Abstract
Background/Aim: In healthy adults, serum insulin-like growth factor I (IGF), IGF-binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) form a 150-kD ternary complex under the control of growth hormone (GH). Circulating IGF-I half-life, bioavailability, and endocrine actions depend on the ternary complex formation. Despite GH hypersecretion, serum IGF-I, IGFBP-3, and ALS levels have all been reported to be low in patients with anorexia nervosa (AN), while the degree of ternary complex formation in AN is unknown. Methods: Serum ALS and 150-kD ternary complex formation were measured in 6 women with AN at the time of diagnosis and after partial weight recovery and in 6 healthy age-matched women serving as controls. Results: Patients with AN had low levels of ALS and IGFBP-3 contained in the 150-kD ternary complex and in the non-150-kD fraction. Following partial weight recovery, the 150-kD IGFBP-3 ternary complex was fully normalized, despite only partial normalization of serum GH and IGF-I levels. Patients with AN did not present with IGFBP-3 proteolysis different from controls. Conclusion: The present data indicate a pivotal role of the nutritional status in the regulation of each of the three components of the 150-kDa ternary IGFBP-3 complex and in the formation of the complex itself.
References
1.
Shimasaki S, Gao L, Shimonaka M, Ling N: Isolation and molecular cloning of insulin-like growth factor-binding protein-6. Mol Endocrinol 1991;5:938–948.
2.
Shimasaki S, Shimonaka M, Zhang HP, Ling N: Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem 1991;266:10646–10653.
3.
Baxter RC: Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 1988;67:265–272.
4.
Baxter RC, Martin JL: Binding proteins for the insulin-like growth factors: Structure, regulation and function. Prog Growth Factor Res 1989;1:49–68.
5.
DeVroede MA, Tseng LY, Katsoyannis PG, Nissley SP, Rechler MM: Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulinlike growth factor carrier proteins released to the incubation media. J Clin Invest 1986;77:602–613.
6.
Conover CA: Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: Studies of underlying mechanism. Endocrinology 1992;130:3191–3199.
7.
Ritvos O, Ranta T, Jalkanen J, Suikkari AM, Voutilainen R, Bohn H, Rutanen EM: Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 1988;122:2150–2157.
8.
Gargosky SE, Wilson KF, Fielder PJ, Vaccarello MA, Guevara-Aguirre J, Diamond FB, Baxter RC, Rosenbloom AL, Rosenfeld RG: The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: Effects of IGF-I therapy on IGFBP-3. J Clin Endocrinol Metab 1993;77:1683–1689.
9.
Gargosky SE, Tapanainen P, Rosenfeld RG: Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology 1994;134:2267–2276.
10.
Masuda A, Shibasaki T, Hotta M, Suematsu H, Shizume K: Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: No evidence of involvement of a low somatomedin-C level in the abnormal GH secretion. J Clin Invest 1988;11:297–302.
11.
Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB: The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 1992;75:762–767.
12.
Golden NH, Kreitzer P, Jacobson MS, Chasalow FI, Schebendach J, Freedman SM, Shenker IR: Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. J Pediatr 1994;125:655–660.
13.
Argente J, Caballo N, Barrios V, Muñoz MT, Pozo J, Chowen JA, Morande G, Hernandez M: Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: Effect of short- and long-term weight recuperation. J Clin Endocrinol Metab 1997;82:2084–2092.
14.
Stoving RK, Flyvbjerg A, Frystyk J, Fisker S, Hangaard J, Hansen-Nord M, Hagen C: Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF-binding protein-3 proteolysis. J Clin Endocrinol Metab 1999;84:1346–1350.
15.
Stoving RK, Veldhuis JD, Flyvbjerg A, Vinten J, Hangaard J, Koldkjær OG, Kristiansen J, Hagen C: Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: Indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J Clin Endocrinol Metab 1999;84:2056–2063.
16.
Fukuda I, Hotta M, Hizuka N, Takano K, Ishikawa Y, Asakawa-Yasumoto K, Tagami E, Demura H: Decreased serum levels of acid-labile subunit in patients with anorexia nervosa. J Clin Endocrinol Metab 1999;84:2034–2036.
17.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, ed 4. Whasington, American Psychiatric Association, 1994, pp 539–545.
18.
Frystyk J, Dinesen B, Orskov H: Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 1995;5:169–176.
19.
Hossenlopp P, Danielle S, Segovia-Quinson B, Hardouin S, Binoux M: Analysis of serum insulin-like growth factor binding proteins using Western blotting: Use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986;154:138–143.
20.
Flyvbjerg A, Kessler U, Dorka B, Funk B, Orskov H, Kiess W: Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 1992;35:589–593.
21.
Bang P, Brismar K, Rosenfeld RG, Hall K: Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulin-dependent diabetes mellitus versus healthy nonobese and obese subjects. J Clin Endocrinol Metab 1994;78:960–967.
22.
Bang P, Brismar K, Rosenfeld RG: Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab 1994:78:1119–1127.
23.
Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA: Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995;80:2282–2288.
24.
Cotterill AM, Holly JM, Taylor AM, Davies SC, Coulson VJ, Preece MA, Wass JA, Savage MO: The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism. J Clin Endocrinol Metab 1992;74:56–63.
25.
Blat C, Villaudy J, Binoux M: In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 1994;93:2286–2290.
26.
Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M: Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 1990;71:797–805.
27.
Lassarre C, Binoux M: Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 1994;134:1254–1262.
28.
Suikkari AM, Baxter RC: Insulin-like growth factor-binding protein-3 is functionally normal in pregnancy serum. J Clin Endocrinol Metab 1992;74:177–183.
29.
Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, Holly JM: The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 1991;130:469–473.
30.
Giudice LC: IGF binding protein-3 protease regulation: How sweet it is! J Clin Endocrinol Metab 1995;80:2279–2281.
31.
Skjærbæk C, Frystyk J, Orskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, Møller N, Flyvbjerg A: Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: The possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 1998;83:2445–2449.
32.
Gargosky SE, Pham HM, Wilson KF, Liu F, Giudice LC, Rosenfeld RG: Measurement and characterization of insulin-like growth factor binding protein-3 in human biological fluids: Discrepancies between radioimmunoassay and ligand blotting. Endocrinology 1992;131:3051–3060.
33.
Lassarre C, Lalou C, Perin L, Binoux M: Protease-induced alteration of insulin-like growth factor binding protein-3 as detected by radioimmunoassay: Agreement with ligand blotting data. Growth Regul 1994;4:48–55.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
